

An efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta

Submission date 23/09/2009	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/01/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 10/05/2019	Condition category Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Francis H Glorieux

Contact details

Shriners Hospitals for Children
1529 Cedar Avenue
Montreal
Canada
H3G 1A6
-
ncyr@shriners.mcgill.ca

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00982124

Secondary identifying numbers

Study information

Scientific Title

An international, multicentre, open-label, efficacy and safety trial of intravenous zoledronic acid in infants less than one year of age, with severe osteogenesis imperfecta

Study objectives

This is an international, multicentre, open-label efficacy and safety trial. The primary objective is to evaluate the change in lumbar spine bone mineral density Z-score at month 24 relative to baseline using intravenous zoledronic acid compared to untreated historical controls in infants with severe osteogenesis imperfecta, who are between 2 weeks and 1 year of age, all inclusive.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Faculty of Medicine, McGill University Institutional Review Board, 08/06/2009, ref: A06-M73-06A

Study design

International multicentre open-label efficacy and safety trial

Primary study design

Interventional

Secondary study design

Non randomised study

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

Health condition(s) or problem(s) studied

Osteogenesis imperfecta

Interventions

All patients will receive an initial infusion of zoledronic acid at 0.0125 mg per kg body weight, followed by infusions of zoledronic acid given every three months at a dose of 0.025 mg per kg body weight, administered as a 30 to 45-minute infusion. There will be a total of 10 visits over the 24 month period of time for all patients. The total number of doses is 8. All zoledronic acid patients will be hospitalised for 48 hours at the first administration of zoledronic acid to monitor for drug reactions. Ionised calcium will be measure pre-dose, 12 hours, 24, 36 and 48 hours post-dose during the hospitalisation period. Sites will call all patients at scheduled monthly visits for

determination of adverse events and concomitant medications throughout the study, except for those months where there is a scheduled on-site visit. Dual energy x-ray absorptiometry (DXA) measurements of the lumbar spine and total body and radiological skeletal survey will be done at screening or at first administration of zoledronic acid, the 12 month visit (visit 6) and final visit (visit 10). Twenty infants will be enrolled; enrolment will be competitive.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Zoledronic acid

Primary outcome measure

Change in lumbar spine bone mineral density Z-score at month 24 relative to baseline in zoledronic acid treated infants with severe osteogenesis imperfecta aged between 2 weeks to 1 year of age at entry, compared to historical controls. The efficacy of zoledronic acid will be demonstrated if it is shown to be a gain in Z-score of at least 1.

Secondary outcome measures

Effect of zoledronic acid on the change in whole body bone mineral content after 12 and 24 months of treatment relative to baseline compared to historical controls in infants 2 weeks to 1 year of age.

Overall study start date

01/10/2009

Completion date

31/12/2012

Eligibility

Key inclusion criteria

1. Children, male or female, 2 weeks to less than 12 months of age, at least at 38 weeks gestational age
2. Any child with phenotypic OI type II, III or IV
3. No previous treatment with bisphosphonates
4. Negative urine protein as measured by dipstick. One repeat assessment of the urine protein will be allowed. The assessment will be made 2 weeks after the first assessment and the sample must be a urine collection after a 4-hour fast

Participant type(s)

Patient

Age group

Child

Lower age limit

2 Weeks

Upper age limit

12 Months

Sex

Both

Target number of participants

20

Key exclusion criteria

1. Blood oxygen saturation of less than 90% in room air
2. Serum creatinine level greater than 56 µmol/L
3. Any clinically significant clinical laboratory abnormalities at screening
4. Treatment with any investigational drug within the past 30 days
5. Patients who are unlikely to be able to complete the study or comply with the visit schedule
6. Any disease or planned therapy which will interfere with the procedures or data collection of this trial

Date of first enrolment

01/10/2009

Date of final enrolment

31/12/2012

Locations

Countries of recruitment

Australia

Belgium

Brazil

Canada

Finland

France

South Africa

United Kingdom

United States of America

Study participating centre

Shriners Hospitals for Children
Montreal
Canada
H3G 1A6

Sponsor information

Organisation

Novartis Pharmaceuticals (Canada)

Sponsor details

385, Boul. Bouchard
Dorval, Québec
Montreal
Canada
H9S 1A9

Sponsor type

Industry

Website

<http://www.novartis.ca/>

ROR

<https://ror.org/05afs3z13>

Funder(s)

Funder type

Industry

Funder Name

Novartis Pharmaceuticals Canada

Alternative Name(s)

Novartis Canada

Funding Body Type

Private sector organisation

Funding Body Subtype

For-profit companies (industry)

Location

Canada

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration